NewG Lab Selects CRO for Global Phase 2 Oral Nafamostat Trial... Development Accelerates

[Asia Economy Reporter Hyungsoo Park] Newgelab announced on the 17th that it has selected Premier Research as the global Phase 2 clinical trial contract research organization (CRO) for the oral COVID-19 treatment drug ‘Newgen Nafamostat Tablets’.

A Newgelab official stated, "Following the metabolic anticancer drug, Premier Research has taken charge of the clinical trial for the oral COVID-19 treatment," adding, "We expect smooth clinical trials through a strategic partnership between the two companies."

Newgelab selected Premier Research as the clinical CRO for the development of the metabolic anticancer drug KAT (Ko Anti-cancer Technology).

Newgen Nafamostat Tablets received clinical trial approval from the Korean Ministry of Food and Drug Safety in November last year. Clinical trials are being conducted at Seoul National University Hospital. After completing the domestic Phase 1 trial, based on the clinical results, Phase 2 trials targeting mild to moderate patients will be conducted in major countries worldwide.

Premier Research, based in the United States, is a global biotech clinical trial specialized contract research organization established in 1989. It employs over 1,600 staff across 84 countries worldwide. In 2018 and 2020, it received the ‘CRO Leadership Award’ from Life Science Leader, a U.S. life sciences industry publication.

This content was produced with the assistance of AI translation services.